Navigation Links
Favrille Announces $21.1 Million Registered Direct Offering
Date:11/2/2007

EF="http://www.sec.gov" target="_new">http://www.sec.gov or from Lazard Capital Markets LLC at 30 Rockefeller Plaza, 60th Floor, New York, NY, 10020.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell non-Hodgkin's lymphoma (NHL) and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma. To receive additional information on the Company, please visit our website at http://www.favrille.com. Information on our website does not, however, form a part of this press release.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the expected closing date for the financing, Favrille's product candidates, proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to whether the offering will close when expected or at all; progress and timing of clinical trials for FavId, including difficulties or delays in development, testing, ma
'/>"/>

SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 iLab Solutions, the leader in core ... Director of Product Strategy. In this role, Michelle will work ... to guide in the development of iLab products. Her main ... possible benefit to the scientific community by offering the most ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... ) and sales and operations planning ( S&OP ) service, ... Biomanufacturing Summit , which will be held at the Hilton ... conference, join Kinaxis customer Elisabeth Kaszas , Director of ...
(Date:1/14/2014)... January 14, 2014 Kerr Corporation, a leading ... and additional how-to information about dual arch impressions on its ... Dual Arch Impressions,” the blog entry serves up a list ... houses a step-by-step demonstration by Dr. David Little as he ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Caliper Life Sciences, Inc. (NASDAQ: CALP ... an innovative sequencing service provider based in Gaithersburg, Md. ... 5500xl, SOLiD 4, and Ion Torrent Personal Genome Machine ... initially focus on sample preparation for exome, whole genome, ...
... EMERYVILLE, Calif., June 27, 2011 MedeAnalytics, a ... announced the launch of its Patient Access Resource ... the front end of the revenue cycle, the ... performance indicators and industry trends, as well as ...
... 2011 Mediabrands, IPG Media Lab and Affectiva ... Festival, the results of the first annual Neuromarketing ... able to record and measure viewers, tacit, non-verbal ... individual,s facial features are established and are then ...
Cached Biology Technology:EdgeBio Selects Caliper's Sample Preparation Suite for High Throughput and Benchtop Sequencing Workflows 2The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 2The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 3
(Date:4/17/2014)... a word for chili peppers. Information about archaeological remains ... study of the appearance of words for chili peppers ... were domesticated and highlight the value of multi-proxy data ... al.) of nine papers presented in a special feature ... of Sciences on plant and animal domestication edited ...
(Date:4/17/2014)... Luca Razzari of the nergie Matriaux Tlcommunications Research ... the John R. Evans Leaders Fund of the ... of state-of-the-art biotech and nanophotonics equipment. To this ... Ministre de l,Enseignement suprieur, de la Recherche, de ... new laboratories will help us develop new approaches ...
(Date:4/17/2014)... University engineer has developed a patented technique that ... devices. The same technique could help police during ... and Kay L. Theede chair in engineering and ... his research team have created a template-based system ... trunks. The distance detection method called stand-off ...
Breaking Biology News(10 mins):Chickens to chili peppers 2Chickens to chili peppers 3New state-of-the-art biotech and nanotech equipment for INRS 2Patented research remotely detects nitrogen-rich explosives 2
... honey bees? How can the spread of the deadly ... enemy? Could the olive fruit fly be similarly controlled? ... what exactly is the Bagrada bug? Entomologists from the ... bug-related questions at a conference on Sept. 19 at the ...
... University and the American Museum of Natural History has ... opposite sides of the Indian Ocean are each other,s ... that these eyeless fishes, one group from Madagascar and ... from a common ancestor before being separated by continental ...
... of a specific mutation in a gene in horses that ... strongly related to racing performance and is advantageous for harness-racing ... impact on their diversification, as the altered gait characteristics of ... a study that includes a Texas A&M University researcher. ...
Cached Biology News:Eyeless Australian fish have closest relatives in Madagascar 2Eyeless Australian fish have closest relatives in Madagascar 3Controlling gait of horses may be possible, says key study from Texas A&M 2
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
96 Well Base Plate...
... ANTI-RNase is a protein ribonuclease inhibitor that noncovalently ... No inhibition is seen with RNase 1, T1, ... distinct from human placental ribonuclease inhibitor in that ... and does not release active RNase in the ...
Biology Products: